High-dose chemotherapy (HDC) was investigated in high-risk neuroblastoma (HR-NBL) to reduce the risk of relapse. We report the results of the 30-year experience of a cohort of patients with HR-NBL treated with high-dose (HD) busulfan (Bu)-containing regimens. From 1980From to 2009 patients aged 41 year with stage 4 NBL were treated with HD Bu-containing regimens at Gustave Roussy. These data were prospectively recorded in the Pediatric Transplantation Database. The median age at diagnosis was 40 months (12-218 months). All patients had a stage 4 neuroblastoma. NMYC amplification was displayed in 24% of the tumors. The hematopoietic support consisted of bone marrow or PBSCs in 46% and 49% of patients, respectively. The 5-year eventfree survival and overall survival rates of the whole cohort were 35.1% and 40%, respectively. Age at diagnosis, bone marrow involvement and tumor response after induction chemotherapy were significant prognostic factors. Toxicity was manageable and decreased over time, owing to both PBSC administration and better supportive care. Based on this experience, HD Bu-melphalan (Mel) has been implemented in Europe and compared with Carboplatin-Etoposide-Mel in the European SIOP Neuroblastoma (SIOPEN)/HR-NBL randomized protocol. It has now become the standard HDC in the SIOPEN HR strategy. 
INTRODUCTION
The improved survival rates of patients with high-risk (HR) neuroblastoma (NBL) observed during the past decades are related to the intensification of induction therapy, high-dose chemotherapy (HDC) and better supportive care. 1 In the HR-NBL population, a correlation between survival and dose intensity has been reported, and three randomized studies showed that HDC followed by autologous stem cell transplantation (ASCT) or autologous bone marrow transplantation (ABMT) improved survival rates. [2] [3] [4] As NBL is notoriously radiosensitive, hyperfractionated TBI was incorporated into the conditioning regimen and has yielded encouraging results. 5 Alkylating agents were demonstrated to produce a log-linear dose response against tumor cells in vitro. 6 Since the mid-1980s, HDC with alkylating agents and ASCT has been the treatment strategy used at Gustave Roussy. HD busulfan (Bu) was selected because of its specific cytotoxicity against quiescent cells, 7 as an alternative to TBI in HR-NBL patients to avoid its side-effects, 8 especially in this very young population, and to achieve better survival rates.
We report here the results of our 30-year experience on patients with HR-NBL treated with HD Bu-containing regimens. Bu was combined with melphalan (Mel) or Mel plus cyclophosphamide, and HDC was followed by stem cell (SC) or bone marrow (BM) transplantation. These results provided the rationale to widely implement the use of HD Bu-Mel, which was then compared with Carboplatin-Etoposide-Mel (CEM) in the European SIOP Neuroblastoma (SIOPEN)/HR-NBL randomized trial. HD Bu-Mel has now become the standard HD regimen in the SIOPEN HR strategy.
PATIENTS AND METHODS Patients
Data concerning patients receiving HDC in the Pediatric and Adolescent Oncology Department at Gustave Roussy were prospectively recorded in the Pediatric Transplantation Database. For patients with neuroblastoma, the criteria to be treated with HDC were as follows: stage 4 NBL 41 year old at diagnosis or stage 3 NBL with NMYC-amplified disease, and at least a PR of metastases after induction chemotherapy. Exclusion criteria were visceral failure or inadequate BM/SC collection. The present study analyzed data concerning all the patients aged 41 year at diagnosis with a stage 4 NBL treated with a Bu-containing regimen registered in the database until June 2009.
Staging and evaluation of disease extent
Staging was performed according to the International Neuroblastoma Staging System. 9 Staging was retrospectively confirmed for patients diagnosed before the introduction of the International Neuroblastoma Staging System. The primary tumor was evaluated by ultrasound and computed tomography or magnetic resonance imaging. Urinary catecholamines were determined in all patients. Disease extent was assessed by 123-iodine metaiodobenzylguanidine (MIBG) or Technetium-99 scintigraphy. At least two biopsies and four aspirates were obtained for morphological evaluation of BM. NMYC amplification has been evaluated since 1985.
Induction therapy
Patients were treated according to the ongoing SFOP/SFCE (French Society of Pediatric Oncology) protocols. Induction chemotherapy was mostly a combination of etoposide, carboplatin, cisplatinum, vincristine, cyclophosphamide or doxorubicin. [10] [11] [12] From 1986 to 1992, Cyclophosphamide was added to the conditioning strategy, and it was administered at a dose of 3600 mg/m 2 , 24 h after Mel. 18 Hematopoietic support SC transplantation was performed 24-48 h after the last dose of HDC. Hematopoietic support was initially performed with purged (ASTA Z) or unpurged autologous BM. 19 Since 1994, PBSC have been collected by leukapheresis either after mobilization with conventional chemotherapy and G-CSF at 5 μg/kg or in steady state with G-CSF at 10 μg/kg. A total of 3 × 10 6 CD34+ cells/kg had to be collected and cryopreserved to allow the administration of HDC.
Supportive care G-CSF was administered (5 μg/kg/day) from day 5 post transplantation until stable neutrophil recovery (4500/mm 3 ). RBCs and platelets were transfused when the hemoglobin level was o8 g/dL and the platelet count was 420 × 10 9 /L or to control bleeding, respectively. All blood products were irradiated (25 Gy).
Clonazepam was administered as seizures prophylaxis during Bu administration. 20 No digestive decontamination was performed. No acyclovir prophylaxis was administered in order to lower drug interactions. 21 Azole antifungal agents were not recommended, neither as a preventive nor as a curative treatment. 22 Since 2005, defibrotide has been administered (25 mg/kg/day IV in four doses) as prophylaxis against sinusoidal occlusion syndrome (SOS). 23 Since 1987, patients are isolated in single laminar airflow rooms until resolution of complications. All patients received trimethoprim-sulfamethoxazole as Pneumocystis Jiroveci prophylaxis.
Other treatments
Resection of the primary tumor was performed before or after HDC. The timing of surgery was dependent on surgical risks. Radiotherapy was administered as a complementary local treatment at a dose of 21 Gy. Since the 2000s, patients have received 6 cycles of retinoic acid (cis-RA; 160 mg/m 2 /day for 14 days every 28 days) as maintenance therapy. 1 
Definition of response
Response was defined as follows: a CR, no detectable disease; and a PR, a decrease of 450% in the number of metastatic sites. A 'good response' was defined as the achievement of a CR after the first line of conventional chemotherapy, whereas a PR or CR obtained after 41 line of conventional chemotherapy were considered as a 'poor response'. Response assessment was performed after the last course of first-line induction therapy and after each line of additional treatment (o 1 month before HDC), 6-8 weeks following HDC and ASCT and at the end of the maintenance therapy.
Evaluation of toxicity
Toxicity was graded according to Bearman criteria. 24 SOS was defined according to McDonald's criteria. 25 
Statistical Methods
The main end point was event-free survival (EFS), defined as the interval from the diagnosis to the time of the first event (progression, relapse, secondary malignancy or death, whatever the cause) or to the date of the last follow-up visit for those with no event. The secondary end points were overall survival (OS), defined as the interval from the diagnosis to the time of death, and toxicity. Categorical variables were described with the numerical count (percentage) of each category and compared by the Chi-square test or Fisher's exact test, when applicable. Continuous variables were described as mean values ± s.d. if the distribution was normal (P40.05, Kolmogorov-Smirnov) and compared by the Student's t-test/analysis of variance or as median and range value if the distribution was not normal and compared by non-parametric tests (Mann-Whitney U-test, Kruskal-Wallis tests). EFS and OS were performed using the Kaplan-Meier method and log-rank test. Multivariate analysis was performed using Cox regression for variables showing P ⩽ 0.2 in the univariate analysis. Data were analyzed using R.3.0.2.
RESULTS

Patient characteristics
From October 1980 to June 2009, 215 patients with HR-NBL were treated with a conditioning regimen containing Bu. Patient characteristics are described in Table 1 . Before HDC, patients received a median number of six courses of conventional chemotherapy (range [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] , over a median duration of 6 months (range 3-23). Good and poor responses after the first line of conventional chemotherapy were obtained in 73 (34%) and 142 (66%) patients, respectively. Consolidation HD oral Bu was administered to 196 patients, with HD Mel in 120 patients and with a combination of HD Mel and cyclophosphamide in 76 patients. Intravenous Bu was administered to 19 children combined with HD Mel. Hematopoietic SC consisted in ABMT in 98 patients until 1995 (46%) and PBSC in 105 patients (49%) since 1994. Seven patients received both PBSC and ABMT owing to insufficient PBSC collection. Allogeneic BM transplantation was performed in five patients. Figure 1 ).
The EFS rates according to age are shown in Figure 2 . Patients aged o 2 years had a significantly better prognosis compared with older children. The 5-year EFS rate was 55.3% (39.7-69.9) and 31.3% (24.8-38.7) (P = 0.02) in children aged o 2 years and in older ones, respectively. Eight out of 19 patients between 12 and 18 months and 6/19 between 18 and 24 months died of disease progression. Six out of 8 and 2/6 had an NMYC-amplified tumor. Two patients, one in each group, died of toxicity. The EFS rates according to age subgroups are shown in Supplementary Figure S1 .
BM involvement at diagnosis was associated with a poorer survival (P = 0.02), with a 5-year EFS rate of 33.1% (26.7-40.1) vs 60% (38.7-78.1) in patients without BM metastases (Figure 3) . NMYC status had no significant impact on the outcome (P = 0.8; Supplementary Figure S2) .
Good response to induction chemotherapy was associated with a significant improvement in terms of survival rates. The 5-year EFS rate was 46.4% (35.2-57.9) and 30% (22.9-38.2%) in good and poor responses, respectively (P = 0.01; Figure 4) .
The adjunction of HD Cyclophosphamide had no effect on survival (P = 0.99; Supplementary Figure S3) , and outcome did not improve over time (P = 0.8; Figure 5 ). The administration of a cis-RA had no significant impact on 5-year EFS and OS rates, which were 34.9% (23.5-48.3%) and 44.2% (31.7-57.5) for patients treated with cis-RA vs 38.5% (30.9-46.8) and 40.6% (32.9-48.9) for the others, respectively ( Figure 6 , P = 0.9; Supplementary Figure S4 , P = 0.6). In a multivariate analysis, age at diagnosis, BM involvement and response to the induction therapy were confirmed as independent prognostic factors (Supplementary Table S1 ). Toxicity All children experienced hematological toxicity with a median duration of neutropenia o 0.5 × 10 9 /L and thrombocytopenia o50 × 10 9 /L lasting 12 days (4-66 days) and 59 days (2-654 days), respectively. Since 1992, 127 patients have received G-CSF after SCT. The median duration of neutropenia, thrombocytopenia and hospitalization significantly decreased over time (Table 2) . In a univariate analysis, the administration of PBSC was associated with a significantly shorter duration of neutropenia, thrombocytopenia and hospitalization compared with BMT, and G-CSF with reduced duration of neutropenia and hospitalization (Table 2) .
Digestive toxicity occurred frequently. Grade ⩾ 3 anorexia and mucositis were the most frequent toxicities observed in 104 (48%) In our cohort, we observed 10 toxic deaths, related to HDC (up to day 100) and to surgery in 8 and 2 patients, respectively. HDC-related deaths were due to severe SOS (5/8), sepsis (2/8) and central nervous system bleeding (1/8), none of which occurred after 1993.
Second tumors. Four patients developed a second tumor (highgrade glioma (1/4), metastatic osteosarcoma (1/4) and papillary thyroid cancer (2/4)). None of these patients had previously received radiotherapy.
DISCUSSION
During the past decades, HDC followed by ASCT has become part of the standard treatment of patients with HR-NBL. The impact of this strategy has been demonstrated by the results of three pediatric randomized trials. [2] [3] [4] These trials explored the impact on survival of consolidation regimens consisting of HD CEM and TBI, 2 
CEM
3 and HD Mel. 4 They showed a significant improvement of survival in patients with stage 4 HR-NBL.
Our cohort does not significantly differ from these series in terms of the median age at diagnosis, sex ratio, the proportion of MYCN amplified tumors and the pattern of metastases. More recently, Matthay et al.
1 published the long-term results of patients treated with CEM+TBI followed by BMT and reported 5-year EFS and OS rates of 30% and 39%, respectively. We report 5-year EFS and OS rates of 35.1% and 40% and 10-year EFS and OS rates of 33.4 and 34.6%, respectively. Based on these results, the HR-NBL1 trial of the SIOPEN Group randomized 598 patients to compare CEM vs Bu-Mel. A significant difference was observed in EFS in favor of Bu-Mel (3-year EFS: 49% vs 33%), as well as in OS (3-year OS: 60% vs 48%). 26 Since 2010, the Bu-Mel regimen is recommended as the standard treatment in the SIOPEN HR-NBL strategy and its administration has been used in other countries.
In our cohort, which has been running since 1980, and in other studies, the age cutoff for pretreatment risk stratification was 12 months, based on the observation that an older age was associated with a worse prognosis. 27 More recently, a very good outcome has been described in children aged 12-18 months with stage 4 NBL, suggesting that 365 days might not be the best cutoff for risk stratification. [28] [29] [30] Consequently, the new International Neuroblastoma Risk Group Staging System extended the age group for stage 4s to patients aged o18 months. 31 In our population, we did not identify a better prognosis in patients aged from 12 to 17 months compared with those aged from 18 to 24 months, but these results might be related to the low number of patients in these two groups. As previously reported, 32 a significantly better outcome was observed in patients aged o24 months compared with older children. The major role of age as a prognostic factor has recently been confirmed in the HR-NBL1/SIOPEN trial cohort. Figure 5 . EFS according to treatment period. High-dose busulfan in high-risk neuroblastoma S Proust-Houdemont et al BM involvement at diagnosis was associated with a worse prognosis, as already demonstrated by Hartmann et al., 32 and a good response to induction therapy seems to be another important prognostic factor in the HR-NBL population, as recently reported by other studies. 1, [34] [35] [36] It is noteworthy that the criteria required to receive HDC differed from those applied in the HR-NBL1/SIOPEN trial. We included patients with a CR or PR of metastases after several lines of chemotherapy ('poor response'), whereas in the SIOPEN study eligibility criteria after Rapid COJEC induction (±2 courses of topotecan with vincristine and doxorubicin) 13, 37 were a CR of BM and a PR on MIBG scan with ⩽ 3 residual positive spots.
The treatment period had no impact on survival, probably because the introduction of the Bu-Mel combination was rapidly followed by better management of HDC-related adverse effects and consequently a very low toxic death rate, and because the response criteria to receive the HD Bu-Mel were the same with time, masking the impact of the induction chemotherapy. Moreover, few patients received a maintenance treatment the impact of which on the long-term survival has still to be defined. In our cohort, the cis-RA maintenance therapy had no significant impact on the prognosis, thus confirming the results reported by Matthay et al.
1
The toxicity profile was manageable. All patients experienced hematological toxicity, and its mean duration decreased over time. Rapid BM reconstitution was achieved by PBSC rescue, with easier SC collection, lower cell contamination and a higher yield of SCs compared with BM grafts. 38, 39 Moreover, the administration of G-CSF reduced the duration of aplasia, thus significantly shortening the duration of hospitalization and overall morbidity. 40 SOS was the most frequent extra-hematological toxicity, with grade ⩾ 3 observed in 8% of patients. These results do not differ from those observed in the HR-NBL1/SIOPEN cohort where grade ⩾ 3 SOS was reported in 5% of patients. 26 SOS has already been linked to the administration of HD Bu, and its severity can be increased by Cyclophosphamide-containing regimens. 41, 42 Importantly, we observed that the duration of SOS decreased over time, and this was probably related to better supportive care and rigorous management of drugs to avoid additional toxicity associated with drug interactions and additive toxic effects on visceral organs. Very few patients had to be transferred to an Intensive Care Unit.
We report 8 HDC-related deaths (3.5%), none of which were observed after 1993. Matthay et al. 2 reported 7% of CEM/TBI-related deaths, and a CEM-related death rate of 3.4% was reported by Berthold et al. 3 In the HR-NBL1/SIOPEN study, the severe toxicity rate up to day 100 was o 10% but higher for CEM than Bu-Mel (P = 0.014). The acute toxic death rate was 3% for Bu-Mel and 5% for CEM. 26 In conclusion, the results of this large single institution cohort study with the first patients treated with this combination showed that HD Bu-Mel is effective and feasible, with an acceptable toxicity profile. Because of the increasing number of survivors and the larger administration of this combination, the assessment of long-term sequelae is now a priority. Abbreviations: ACST = autologous stem cell transplantation; BM = bone marrow.
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